Basilea Pharmaceutica Announces Submission of Marketing Authorization Application in Europe by Janssen-Cilag International NV (JNJ) for Ceftobiprole, a Novel Anti-MRSA Broad-spectrum Cephalosporin  
6/18/2007 10:43:05 AM

Basel, Switzerland, June 18, 2007 - Basilea Pharmaceutica Ltd. (Swiss:BSLN.SW - News) announced today the submission of a Marketing Authorization Application to the European Medicines Agency (EMEA) for ceftobiprole by its license partner Janssen-Cilag International NV, a Johnson & Johnson company. This submission is for the use of ceftobiprole in the treatment of complicated skin and soft tissue infections (cSSTI) including diabetic foot infections. Ceftobiprole is the first anti-MRSA broad-spectrum cephalosporin antibiotic to complete Phase III clinical trials.